Creutzfeldt-Jakob disease (CJD) can be difficult to distinguish clinically from some non-prion neurological diseases. Previous studies have reported markedly increased levels of α-synuclein in cerebrospinal fluid (CSF) of CJD patients, indicating that it is a potential diagnostic biomarker.
Objective:
The aim of this study was to assess the diagnostic power of CSF α-synuclein in discriminating CJD from non-prion disorders.
Methods:
The Ovid MEDLINE, Cochrane, and Embase databases were searched for articles published on or before February 25, 2022, using the search term (prion diseases OR Creutzfeldt-Jakob syndrome) AND (synuclein OR α-synuclein). The difference in CSF α-synuclein levels between CJD and non-prion diseases was calculated using random-effects models (I2 > 50%) or fixed-effects models (I2 < 50%) in terms of standardized mean difference (SMD) and 95% confidence interval (CI). The publication bias was estimated using funnel plots and the Egger’s test.
Results:
Ten studies were included in this study. The concentrations of CSF α-synuclein were significantly higher in CJD patients compared to total non-prion controls (SMD = 1.98, 95% CI 1.60 to 2.36, p < 0.00001), tauopathies (SMD = 1.34, 95% CI 0.99 to 1.68, p < 0.00001), synucleinopathies (SMD = 1.78, 95% CI 1.11 to 2.44, p < 0.00001), or Alzheimer’s (SMD = 1.14, 95% CI 0.95 to 1.33, p < 0.00001). CSF α-synuclein could distinguish CJD from non-prion diseases with overall sensitivity of 89% (95% CI 80–95%), specificity of 92% (95% CI 86–95%), and AUC of 0.96 (95% CI: 0.94–0.97).
Conclusion:
CSF α-synuclein has excellent diagnostic value in discriminating CJD from non-prion neurological diseases. Given the high heterogeneity among the included studies, further studies are needed to confirm its clinical utility.
ZanussoG, MonacoS, PocchiariM, CaugheyB (2016) Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease. Nat Rev Neurol12, 325–333.
2.
Abu-RumeilehS, BaiardiS, PolischiB, MammanaA, FranceschiniA, GreenA, CapellariS, ParchiP (2019) Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC. J Neurol266, 3136–3143.
3.
LlorensF, KruseN, KarchA, SchmitzM, ZafarS, GotzmannN, SunT, KochyS, KnipperT, CrammM, GolanskaE, SikorskaB, LiberskiPP, Sanchez-ValleR, FischerA, MollenhauerB, ZerrI (2018) Validation of alpha-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease. Mol Neurobiol55, 2249–2257.
4.
LlorensF, KruseN, SchmitzM, GotzmannN, GolanskaE, ThüneK, ZejneliO, KanataE, KnipperT, CrammM, LangeP, ZafarS, SikorskaB, LiberskiPP, MitrovaE, VargesD, SchmidtC, SklaviadisT, MollenhauerB, ZerrI (2017) Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. Alzheimers Dement13, 710–719.
5.
SpillantiniMG, GoedertM (2000) The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci920, 16–27.
6.
FournierJG (2008) Cellular prion protein electron microscopy: Attempts/limits and clues to a synaptic trait. implications in neurodegeneration process. Cell Tissue Res332, 1–11.
7.
ClintonJ, ForsythC, RoystonMC, RobertsGW (1993) Synaptic degeneration is the primary neuropathological feature in prion disease: A preliminary study. Neuroreport4, 65–68.
8.
JeffreyM, HallidayWG, BellJ, JohnstonAR, MacLeodNK, InghamC, SayersAR, BrownDA, FraserJR (2000) Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol26, 41–54.
9.
MastrangeloA, BaiardiS, ZenesiniC, PoleggiA, MammanaA, PolischiB, LadoganaA, CapellariS, ParchiP (2021) Diagnostic and prognostic performance of CSF alpha-synuclein in prion disease in the context of rapidly progressive dementia. Alzheimers Dement (Amst)13, e12214.
10.
FayolleM, LehmannS, DelabyC (2022) Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt–Jakob disease in clinical practice. J Neural Transm (Vienna)129, 133–139.
11.
KruseN, HeslegraveA, GuptaV, FoianiM, Villar-PiquéA, SchmitzM, LehmannS, TeunissenC, BlennowK, ZetterbergH, MollenhauerB, ZerrI, LlorensF (2018) Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. Alzheimers Dement (Amst)10, 461–470.
12.
RübsamenN, PapeS, KonigorskiS, ZapfA, RückerG, KarchA (2022) Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: A (network) meta-analysis. Eur J Neurol29, 1366–1376.
CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD) (2018) Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP).
ParchiP, de BoniL, SaverioniD, CohenML, FerrerI, GambettiP, GelpiE, GiacconeG, HauwJJ, HöftbergerR, IronsideJW, JansenC, KovacsGG, RozemullerA, SeilheanD, TagliaviniF, GieseA, KretzschmarHA (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol124, 517–529.
17.
WanX, WangW, LiuJ, TongT (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol14, 135.
18.
Diaz-LucenaD, EscaramisG, Villar-PiquéA, HermannP, SchmitzM, VargesD, SantanaI, del RioJA, MartíE, FerrerI, BaldeirasI, ZerrI, LlorensF (2020) A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia. J Neurol267, 2567–2581.
19.
LlorensF, KruseN, SchmitzM, ShafiqM, da CunhaJE, GotzmanN, ZafarS, ThuneK, de OliveiraJR, MollenhauerB, ZerrI (2015) Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD. J Neurol262, 2305–2311.
20.
OecklP, MetzgerF, NaglM, von ArnimCA, HalbgebauerS, SteinackerP, LudolphAC, OttoM (2016) Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer’s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics15, 3126–3138.
21.
SchmitzM, Villar-PiquéA, LlorensF, GmitterováK, HermannP, VargesD, ZafarS, LingorP, VandersticheleH, DemeyerL, StoopsE, TrojanowskiJQ, LeeVM, ZerrI (2019) Cerebrospinal fluid total and phosphorylated α-synuclein in patients with Creutzfeldt–Jakob disease and synucleinopathy. Mol Neurobiol56, 3476–3483.
22.
MollenhauerB, CullenV, KahnI, KrastinsB, OuteiroTF, PepivaniI, NgJ, Schulz-SchaefferW, KretzschmarHA, McLeanPJ, TrenkwalderC, SarracinoDA, VonSattelJP, LocascioJJ, El-AgnafOMA, SchlossmacherMG (2008) Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol213, 315–325.
MollenhauerB, LocascioJJ, Schulz-SchaefferW, Sixel-DöringF, TrenkwalderC, SchlossmacherMG (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol10, 230–240.
25.
van SteenovenI, MajbourNK, VaikathNN, BerendseHW, van der FlierWM, van de BergWDJ, TeunissenCE, LemstraAW, El-AgnafOMA (2018) α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies. Mov Disord33, 1724–1733.
26.
JakesR, SpillantiniMG, GoedertM (1994) Identification of two distinct synucleins from human brain. FEBS Lett345, 27–32.
27.
MaroteauxL, CampanelliJT, SchellerRH (1988) Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci8, 2804–2815.
28.
KitamotoT, ShinRW, Doh-uraK, TomokaneN, MiyazonoM, MuramotoT, TateishiJ (1992) Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol140, 1285–1294.
29.
KasaiT, TokudaT, IshiiR, IshigamiN, TsuboiY, NakagawaM, MizunoT, El-AgnafOMA (2014) Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol261, 1203–1209.
30.
HuangN, MarieSK, LivramentoJA, ChammasR, NitriniR (2003) 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology61, 354–357.
31.
LlorensF, SchmitzM, KarchA, CrammM, LangeP, GheribK, VargesD, SchmidtC, ZerrI, StoeckK (2016) Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement12, 577–589.
32.
SchoonenboomNS, ReesinkFE, VerweyNA, KesterMI, TeunissenCE, van de VenPM, PijnenburgYA, BlankensteinMA, RozemullerAJ, ScheltensP, van der FlierWM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology78, 47–54.
AkagiA, IwasakiY, HashimotoR, AibaI, InukaiA, MimuroM, RikuY, MiyaharaH, KitamotoT, YoshidaM (2020) A case of M232R genetic Creutzfeldt-Jakob disease with Lewy bodies. J Neurol Sci409, 116605.
35.
KoideT, OhtakeH, NakajimaT, FurukawaH, SakaiK, KameiH, MakifuchiT, FukuharaN (2002) A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. Neurology59, 1619–1621.
36.
Bengoa-VergnioryN, RobertsRF, Wade-MartinsR, Alegre-AbarrateguiJ (2017) Alpha-synuclein oligomers: A new hope. Acta Neuropathol134, 819–838.
37.
El-AgnafOM, WalshDM, AllsopD (2003) Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol2, 461–462.
38.
MajbourNK, VaikathNN, van DijkKD, ArdahMT, VargheseS, VesteragerLB, MontezinhoLP, PooleS, Safieh-GarabedianB, TokudaT, TeunissenCE, BerendseHW, van de BergWD, El-AgnafOM (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener11, 7.
39.
MollenhauerB, BowmanFD, DrakeD, DuongJ, BlennowK, El-AgnafO, ShawLM, MasucciJ, TaylorP, UmekRM, DuntyJM, SmithCL, StoopsE, VandersticheleH, SchmidAW, MoniatteM, ZhangJ, KruseN, LashuelHA, TeunissenC, SchubertT, DaveKD, HuttenSJ, ZetterbergH (2019) Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. J Neurochem149, 126–138.
40.
del CampoM, MollenhauerB, BertolottoA, EngelborghsS, HampelH, SimonsenAH, KapakiE, KruseN, Le BastardN, LehmannS, MolinuevoJL, ParnettiL, Perret-LiaudetA, Sáez-ValeroJ, SakaE, UrbaniA, VanmechelenE, VerbeekM, VisserPJ, TeunissenC (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. Biomark Med6, 419–430.
41.
AbdiIY, MajbourNK, WillemseEAJ, van de BergWDJ, MollenhauerB, TeunissenCE, El-AgnafOM (2021) Preanalytical stability of CSF total and oligomeric alpha-synuclein. Front Aging Neurosci13, 638718.
